Your search for non small cell lung cancer returned 432 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for non small cell lung cancer returned 432 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Phase 3 study of ARQ 197 for non small cell lung cancer (NSCLC)

Daiichi Sankyo and ArQule announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197 in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Drugs in the Pipeline

Phase 2 study of ARQ 197 for non small cell lung cancer (NSCLC)

ArQule and Daiichi Sankyo announced the presentation of data from a Phase 2 trial showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer (NSCLC).
News

Tecentriq Approved for Non-Small Cell Lung Cancer

Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.